Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp-Reference-Cited by-同舟云学术

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp

Published:2023-09 Issue: Volume:191 Page:112986
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hassel Jessica C.,Berking Carola,Forschner Andrea^ORCID,Gebhardt Christoffer^ORCID,Heinzerling Lucie,Meier Friedegund^ORCID,Ochsenreither Sebastian,Siveke Jens^ORCID,Hauschild Axel,Schadendorf Dirk

Funder

American Medical Systems

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference38 articles.

1. Tebentafusp: T cell redirection for the treatment of metastatic uveal melanoma;Damato;Cancers,2019

2. Polyfunctional response by ImmTAC (IMCgp100) redirected CD8(+) and CD4(+) T cells;Boudousquie;Immunology,2017

3. Kimmtrak Summary of Product Characteristics. 2022.

4. Redirecting polyclonal T cells against cancer with soluble T cell receptors;Berman;Clin Cancer Res,2022

5. Overall survival benefit with tebentafusp in metastatic uveal melanoma.;Nathan;N Engl J Med,2021

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineered T cells for Colorectal Cancer;Immunotherapy;2024-09-04

2. T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma;Pharmaceutics;2024-08-06

3. Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review;European Journal of Cancer;2024-07

4. Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action;Journal of Investigative Dermatology;2024-07

5. The Current State of Systemic Therapy of Metastatic Uveal Melanoma;American Journal of Clinical Dermatology;2024-06-22